BR112017007386A2 - compostos de carboxilato fenilcetona e composições farmacêuticas para prevenção e tratamento de osteoporose - Google Patents

compostos de carboxilato fenilcetona e composições farmacêuticas para prevenção e tratamento de osteoporose

Info

Publication number
BR112017007386A2
BR112017007386A2 BR112017007386-2A BR112017007386A BR112017007386A2 BR 112017007386 A2 BR112017007386 A2 BR 112017007386A2 BR 112017007386 A BR112017007386 A BR 112017007386A BR 112017007386 A2 BR112017007386 A2 BR 112017007386A2
Authority
BR
Brazil
Prior art keywords
mcooh
osteoporosis
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
BR112017007386-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Gagnon Lyne
Grouix Brigitte
Original Assignee
Prometic Pharma Smt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Limited filed Critical Prometic Pharma Smt Limited
Publication of BR112017007386A2 publication Critical patent/BR112017007386A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017007386-2A 2014-10-10 2015-10-08 compostos de carboxilato fenilcetona e composições farmacêuticas para prevenção e tratamento de osteoporose BR112017007386A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062660P 2014-10-10 2014-10-10
US62/062,660 2014-10-10
PCT/CA2015/000530 WO2016054725A1 (en) 2014-10-10 2015-10-08 Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (1)

Publication Number Publication Date
BR112017007386A2 true BR112017007386A2 (pt) 2018-01-23

Family

ID=55652426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007386-2A BR112017007386A2 (pt) 2014-10-10 2015-10-08 compostos de carboxilato fenilcetona e composições farmacêuticas para prevenção e tratamento de osteoporose

Country Status (22)

Country Link
US (1) US10925846B2 (enExample)
EP (1) EP3204000B1 (enExample)
JP (1) JP6700638B2 (enExample)
KR (1) KR20170066613A (enExample)
CN (1) CN106999459B (enExample)
AR (1) AR102247A1 (enExample)
AU (1) AU2015330642B2 (enExample)
BR (1) BR112017007386A2 (enExample)
CA (1) CA2963358C (enExample)
DK (1) DK3204000T3 (enExample)
ES (1) ES2794782T3 (enExample)
IL (1) IL251409B (enExample)
MX (1) MX376880B (enExample)
MY (1) MY187511A (enExample)
PH (1) PH12017500636A1 (enExample)
PL (1) PL3204000T3 (enExample)
PT (1) PT3204000T (enExample)
RU (1) RU2712027C2 (enExample)
SG (1) SG11201702810TA (enExample)
TW (1) TWI723962B (enExample)
UY (1) UY36355A (enExample)
WO (1) WO2016054725A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
CA2777629C (en) * 2009-10-14 2018-02-13 The Governors Of The University Of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
US20130225683A1 (en) * 2010-10-27 2013-08-29 Prometic Biosciences Inc. Compounds and Pharmaceutical Compositions for Uses in Diabetes
PH12013500763B1 (en) * 2010-10-27 2018-07-04 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical uses thereof
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
WO2014138372A1 (en) * 2013-03-06 2014-09-12 Primavera Biosciences, Inc. Composition and method for treating osteoarthritis
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy

Also Published As

Publication number Publication date
CA2963358A1 (en) 2016-04-14
TW201618761A (zh) 2016-06-01
SG11201702810TA (en) 2017-05-30
IL251409B (en) 2020-08-31
UY36355A (es) 2016-06-01
CN106999459B (zh) 2020-07-10
PT3204000T (pt) 2020-05-06
RU2017116154A (ru) 2018-11-12
AU2015330642A1 (en) 2017-05-11
PH12017500636A1 (en) 2017-09-25
ES2794782T3 (es) 2020-11-19
CN106999459A (zh) 2017-08-01
EP3204000B1 (en) 2020-01-08
TWI723962B (zh) 2021-04-11
DK3204000T3 (da) 2020-04-06
WO2016054725A1 (en) 2016-04-14
IL251409A0 (en) 2017-05-29
EP3204000A1 (en) 2017-08-16
AR102247A1 (es) 2017-02-15
JP6700638B2 (ja) 2020-05-27
US20190038580A1 (en) 2019-02-07
CA2963358C (en) 2023-03-07
RU2712027C2 (ru) 2020-01-27
MX376880B (es) 2025-03-07
PL3204000T3 (pl) 2020-07-27
KR20170066613A (ko) 2017-06-14
JP2017530179A (ja) 2017-10-12
MY187511A (en) 2021-09-24
US10925846B2 (en) 2021-02-23
AU2015330642B2 (en) 2019-07-04
EP3204000A4 (en) 2018-06-20
RU2017116154A3 (enExample) 2019-05-06
MX2017004735A (es) 2017-11-17

Similar Documents

Publication Publication Date Title
BR112017007426A2 (pt) compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose
JOP20210319B1 (ar) مركبات بيروليدين
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX395482B (es) Compuestos antiproliferativos y metodos de uso de los mismos
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12018502457B1 (en) Treatment for parkinson's disease
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX2020012336A (es) Formulacion farmaceutica.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
FI3273968T3 (fi) Minosykliiniyhdisteitä biopuolustukseen
WO2017020874A3 (es) Metodo para el tratamiento de las enfermedades de plantas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]